Search - tctmd.com

Displaying 41 - 60 of 247

Sort: Relevancy | Date

Presentation ESC 2024

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Presenter: Stefano Taddei

August 31, 2024

Presentation ESC 2024

Continuation versus Interruption of Oral Anticoagulation during TAVI

Presenter: Dirk-Jan van Ginkel

August 31, 2024

News Conference News ESC 2024

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

Yael L. Maxwell

August 31, 2024

News Conference News ESC 2024

Polypills Show Promise in Diverse Hypertensive Patient Groups

L.A. McKeown

August 31, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

L.A. McKeown

July 02, 2024

News Daily News

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

Michael O'Riordan

June 24, 2024

News Daily News

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

L.A. McKeown

May 17, 2024

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

News Conference News ESC Heart Failure 2024

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

Michael O'Riordan

May 13, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Conference News ESC 2023

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

Michael O'Riordan

September 06, 2023

News Conference News ESC 2023

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

L.A. McKeown

September 01, 2023

News Conference News ESC 2023

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

Michael O'Riordan

September 01, 2023

News Conference News ESC 2023

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

Michael O'Riordan

August 31, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Conference News ESC 2023

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Caitlin E. Cox

August 30, 2023

News ESC 2023

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Michael O'Riordan

August 27, 2023

Advertisement

QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension

Continuation versus Interruption of Oral Anticoagulation during TAVI

New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day

Polypills Show Promise in Diverse Hypertensive Patient Groups

Scientific Statement Reviews Current Antithrombotic Options in PAD

Aligning Pill Burden and Palliative Care Needs in Late-Stage CVD: AHA

Vutrisiran, an siRNA for ATTR-CM, Meets Primary Endpoint in HELIOS-B

AHA/ACC and Others Issue PAD Guideline Update With Focus on Collaborative Care

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

SEQUOIA-HCM: Aficamten Boosts Exercise Capacity in Obstructive HCM

April 2024 Dispatch for the CV Team

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More

ESC Focused Update on HF Synthesizes New Trial Data for Practical Use

ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran

More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground

Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content